Analyst Ratings For BIOC – Biocept (NASDAQ:BIOC)
Today, Westpark Capital reiterated its Outperform rating on BIOC – Biocept (NASDAQ:BIOC) with a price target of $1.00.
Some recent analyst ratings include
- 4/4/2018-Westpark Capital Reiterated Rating of Outperform.
- 11/14/2017-Chardan Capital Reiterated Rating of Buy .
- 3/13/2017-Roth Capital Reiterated Rating of Buy.
- 11/10/2016-Feltl & Co. Upgrade from a “Hold ” rating to a ” Buy” rating.
Recent Insider Trading Activity For BIOC – Biocept (NASDAQ:BIOC)
BIOC – Biocept (NASDAQ:BIOC) has insider ownership of 7.70% and institutional ownership of 9.29%.
- On 10/19/2016 Claire Reiss, Major Shareholder, bought 227,272 with an average share price of $1.10 per share and the total transaction amounting to $249,999.20.
- On 10/19/2016 David F. Hale, Director, bought 90,909 with an average share price of $1.10 per share and the total transaction amounting to $99,999.90.
- On 10/19/2016 Lyle J. Arnold, SVP, bought 45,000 with an average share price of $1.10 per share and the total transaction amounting to $49,500.00.
- On 10/19/2016 Timothy Kennedy, CFO, bought 36,363 with an average share price of $1.10 per share and the total transaction amounting to $39,999.30.
- On 5/4/2016 Bruce Gerhardt, Director, bought 25,000 with an average share price of $1.00 per share and the total transaction amounting to $25,000.00.
- On 5/4/2016 Claire Reiss, Major Shareholder, bought 614,273 with an average share price of $1.00 per share and the total transaction amounting to $614,273.00.
- On 2/13/2015 David F Hale, Chairman, bought 40,000 with an average share price of $1.25 per share and the total transaction amounting to $50,000.00.
Recent Trading Activity for BIOC – Biocept (NASDAQ:BIOC)
Shares of BIOC – Biocept closed the previous trading session at 0.24 -0.00 1.84% with 0.2502000033855438 shares trading hands.